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Abstract
Aim. Technological and computational advancements offer new tools for the collection and
analysis of real-world data (RWD). Considering the substantial effort and resources devoted to
collecting RWD, a greater return would be achieved if real-world evidence (RWE) was effec-
tively used to support Health Technology Assessment (HTA) and decision making on medical
technologies. A useful question is: To what extent are RWD suitable for generating RWE?
Methods. We mapped existing RWD sources in Europe for three case studies: hip and knee
arthroplasty, transcatheter aortic valve implantation (TAVI) and mitral valve repair (TMVR),
and robotic surgery procedures. We provided a comprehensive assessment of their content
and appropriateness for conducting the HTA of medical devices. The identification of
RWD sources was performed combining a systematic search on PubMed with gray literature
scoping, covering fifteen European countries.
Results. We identified seventy-one RWD sources on arthroplasties; ninety-five on TAVI and
TMVR; and seventy-seven on robotic procedures. The number, content, and integrity of the
sources varied dramatically across countries. Most sources included at least one health out-
come (97.5%), with mortality and rehospitalization/reoperation the most common; 80% of
sources included resource outcomes, with length of stay the most common, and comparators
were available in almost 70% of sources.
Conclusions. RWD sources bear the potential for the HTA of medical devices. The main
challenges are data accessibility, a lack of standardization of health and economic outcomes,
and inadequate comparators. These findings are crucial to enabling the incorporation of RWD
into decision making and represent a readily available tool for getting acquainted with existing
information sources.
Introduction
Over the last few decades, digital innovation has permitted the generation, collection, and stor-
age of a large volume of health-related data that can be employed to track patients’ health and
to monitor health service delivery and technologies during all stages of the lifecycle.
Observational or administrative data that provide information on the routine delivery of health
care and the health status of the target population are defined real-world data (RWD) (1).
RWD can be medical health records, registries, biobanks, administrative data, health surveys,
observational studies, health insurance data, data generated from mobile applications, etc. (2).
The increasing availability of RWD has generated much attention in assessing whether, and if
so to what extent, they can be used to generate clinical evidence regarding the usage, and
potential benefits or risks, of medical technologies. In the Health Technology Assessment
(HTA) glossary (htaglossary.net), evidence derived from RWD analyses is defined as real-
world evidence (RWE).
RWE is particularly important for medical devices because, for this class of technology,
available clinical evidence is traditionally of a lower standard, at least when compared with
drug technologies. Clinical trials are often impeded by problems, including difficulties in
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the blinding process, learning curve issues, hospital processes that
may influence outcomes, incremental innovation, and fast prod-
uct modification, with high loss to follow-up (3). In the literature,
several issues with RWE use have been discussed by different
stakeholders, often without distinguishing between medical
devices and pharmaceuticals. Typical concerns with RWD use
include confounding biases and limitations from measurement
errors, selection bias, time-related bias, reverse causality, etc.
(4;5). If RWD sources prove to be of adequate quality (i.e.,
based on suitable data collection protocols), it is fundamental
developing a statistical analysis plan (e.g., checking covariate bal-
ance after applying the chosen confounding adjustment strategy,
checking statistical power, evaluating positive or negative control
outcomes, detailing the selection of the study population, and
specifying primary vs. secondary analyses) (6). Possible RWE
uses acknowledged in the literature and by the HTA community
include regulatory processes such as market authorization (in the
USA), postmarket surveillance, payer coverage, and reimburse-
ment (7). RWE may be used over the whole product lifecycle,
from the development of a new health technology, through the
market access phase and post launch. RWE is recognized as a
promising source of information for market access and reim-
bursement and as a complement to clinical trial evidence for
treatment pathways, resource use, long-term natural history, and
cost-effectiveness (8). RWD have also been increasingly used, in
addition to randomized controlled trials (RCTs), for cost-
effectiveness analyses (9) and for reassessments, payer coverage
decisions, and outcome-based contracting (1;10). In a document
issued in 2017, the FDA reported that RWD may potentially be
used on their own or together with other evidence for under-
standing medical device performance at different points in the
product lifecycle (11).
However, any potential use of RWD is conditional on their
quality, relevance, and reliability. In a recent Health Technology
Assessment International (HTAi) Policy Forum, it was noted
that there is a lack of agreement between different parties regard-
ing what data are needed, when, and for what purpose. Indeed,
there is no clear consensus among stakeholders about when to
use RWD (1): “The HTA community is currently standing at a
cross-road, as it is not yet fully equipped to address these key chal-
lenges” (12). Therefore, it is important to explore these issues,
especially for health technologies such as medical devices,
where HTA may rely heavily on RWD.
This study aims to offer new tools for addressing some of these
challenges, providing empirical evidence on the use of RWD for
the HTA of medical devices. To achieve this general goal, we (i)
systematically mapped RWD sources in Europe for three selected
case studies: hip and knee arthroplasty, percutaneous transcath-
eter valve replacement technology (transcatheter aortic valve
implantation [TAVI] and transcatheter mitral valve repair
[TMVR]), and procedures performed by the da Vinci Surgical
System. Then, we (ii) provided a comprehensive assessment of
their content and evaluated their appropriateness for conducting
the HTA of medical devices.
Methods
Choice of Case Studies
RWD source mapping was performed for the three case studies of
medical devices: (i) hip and knee arthroplasty, (ii) TAVI and
TMVR, and (iii) the da Vinci Surgical System. The choice of
case studies was not intended to be representative of all types of
medical devices, but rather to cover a spectrum of heterogeneous
cases in terms of the epidemiology of diseases, demographic
trends (e.g., population ageing), characteristics of the procedures,
and the maturity and type of the technology. Supplementary
Table 1 shows, in a comparative way, the key characteristics of
the three medical technologies selected, providing details on
their maturity, EU classification, indication, and epidemiologi-
cal/demographic characteristics and forecasts.
Types of RWD
The identification of RWD sources for each case study was based
on an adaptation of the classification of Makady et al. (13). To get
a complete overview of the main RWD sources, we considered the
following sources and study designs for inclusion: (i) administra-
tive data, (ii) registry data, and (iii) other observational data. Data
that could not be assigned to any of the categories were defined as
(iv) other data. Registries are a specific type of observational data,
where information about the health status of patients and the
health care they receive over varying periods of time are typically
recorded. Given that they play a prominent role in market/clinical
surveillance, we included them as a separate category, alongside
other observational data, such as health surveys and hospital data.
Search Strategy
To map RWD sources for medical devices, multiple search strat-
egies were adopted and implemented for each case study. We per-
formed a systematic literature review, a targeted search of the gray
literature and the Web sites of governments, research institutes,
and relevant public agencies. In addition, we sought advice
from experts in the devices and procedures/diseases of interest.
The systematic search was performed using PubMed. The
search was developed to combine terms referring to the selected
RWD types, with either the disease or the procedure or the med-
ical device pertaining to the case study, and with the countries
included in the mapping. The set of key words is available in
Supplementary Table 2. The inclusion and exclusion criteria
were set so as to match RWD definitions, the diseases, procedures,
and medical devices, and geographic settings. More specifically,
studies that used data sources not listed among selected RWD
types were excluded; studies that used selected RWD types, but
that were conducted by a single research unit (e.g., one hospital
and patients of one surgeon) were excluded because we aimed
to map RWD sources that provided generalizable data. This
“single-center” exclusion criterion was not applied to da Vinci
robotic surgery because less evidence is available, and single
research unit studies often represent the only available RWD
source. Furthermore, single-center studies were included in the
first and second case study when considered particularly relevant
(e.g., because many patients were included). There were other
exclusions: nonempirical studies (e.g., literature reviews and com-
mentaries), studies dealing with neither the disease nor procedure
nor device of interest, studies outside the countries of interest, and
studies based on data collected before 2013 because we wanted to
identify information relevant to present-day decision making. For
each search, the screening and study selection were illustrated
through an adapted version of the PRISMA flowchart.
Gray literature scoping consisted in screening national/
European sources, such as webpages and online archives to gain
a general overview of the accessibility and breadth of data
2 Benedetta Pongiglione et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0266462321000301
Downloaded from https://www.cambridge.org/core. IP address: 86.182.126.50, on 11 May 2021 at 11:03:54, subject to the Cambridge Core terms of use, available at
knowledge related to each case study. There was also a nonsystem-
atic search on Google Scholar.
At least one author from the countries represented in the
research team (namely, Italy, Germany, England and Wales,
Netherlands, Hungary, and Switzerland) performed the search
for his or her country, so that it was possible to consult relevant
national sources in the national language. Additional European
countries, not represented in the research team, were also
included, and these were selected based on the authors’ knowl-
edge of local language and context (see Supplementary
Table 3). International sources, involving multiple European
countries, were also mapped and were given a separate setting.
Finally, after performing a systematic search and gray literature
scoping, advice from experts with the devices, procedures, and/or
diseases was sought. This was done to assess the completeness and
quality of the mapping.
Information Extraction
Information on each of the RWD sources was extracted and
entered into a spreadsheet that synthesizes the general features
of the sources and the variables included and that provides the
references and links for each source. The extraction template
was created for each case study, with each row providing informa-
tion on a single RWD source. In Supplementary Tables 4 and 5,
the general framework of the template and definitions for each
field are presented.
Results
In total, mapping covered fifteen countries, plus multinational/
European sources. We identified seventy-one RWD sources on
hip and knee arthroplasties, ninety-five sources on TAVI and
TMVR, and seventy-one on the da Vinci surgical system. A com-
plete list of sources with full details is provided in the extraction
template available in Supplementary Table 6. Supplementary
Figure 1 shows PRISMA flowchart with the screening results of
the PubMed search.
The number of sources varied substantially across countries for
each case study. Germany was the country with the highest num-
ber of sources, followed by multinational sources and Italy
(Supplementary Figure 2). Of the seventy-one sources found for
arthroplasty, almost half (thirty-four) are registry data, 32 percent
(twenty-three) other observational data, and 17 percent (twelve)
administrative data, with two sources categorized as other data.
Other data are the Network of Orthopaedic Registries of Europe
and European Arthroplasty Registry. These are international reg-
istry networks rather than actual registries, so they are categorized
separately. A similar distribution of sources is observed for RWD
on TAVI and TMVR: 60 percent are registry data (fifty-seven),
34.7 percent are other observational data (thirty-three), and 5.3
percent are administrative data (five). For the da Vinci robot,
84.5 percent are classified as other observational data (sixty), 11
percent are registry data (eight), and 4 percent administrative
data (three).
General Features
The general characteristics of the selected sources were the data
aggregation level (i.e., the unit of analysis), data accessibility, geo-
graphic coverage, and the approach for selecting the sample. The
results are synthesized in Table 1 by case study, and discussed
here, distinguishing the RWD type. In terms of their aggregation
level, most sources had, in all case studies, patient-level data, but
the proportion was lower for arthroplasties. Accessibility to data
in most cases was limited, either restricted or private (distinction
of terms provided in Supplementary Table 5). Nonregistry obser-
vational data were the most difficult to access; hence, data on the
da Vinci robot, that mainly came from this source, were most
commonly private. Regarding geographical coverage, the highest
proportion of transnational sources was for TAVI and TMVR,
whereas national coverage was particularly common for arthro-
plasty, due to the national registries set up in most European
countries. Single-center sources of RWD were included only for
the da Vinci robot, and they represented half of the existing
sources. Finally, for arthroplasty, around 45.1 percent of sources
selected patients based on their disease and 36.6 percent based
on medical device (either single or multiple devices). For TAVI
and TMVR, two thirds of RWD sources were either single or mul-
tiple medical device-based. This mainly depended on the fact that
two prostheses are most commonly used in clinical practice, the
Edwards SAPIEN valve (Edwards Life-sciences, Irvine, CA,
USA) and the CoreValve System (Medtronic Inc., Minneapolis,
MN, USA). Many studies were sponsored by these manufacturers.
For robotic surgery, almost half of the RWD sources were either
single- or multiple-device-based. Many studies compared robotic
surgery with laparoscopic or open interventions, and their inclu-
sion approach was classified as “other.”











Patient 88.7 94.7 94.4
Hospital 2.8 3.2 4.2
Region (NUTS2) 0 0 1.4
Country 8.5 2.1 0
Data accessibility (%)
Public 7.1 1.1 0
Restricted 57.7 34.7 28.2
Private 16.9 36.8 53.5
Other 18.3 27.4 18.3
Geographical coverage (%)
Single center na na 49.3
Subnational/multicenter 32.4 29.5 15.5
National 56.3 35.8 26.8
Transnational 11.3 34.7 8.5
Inclusion approach (%)
Disease-based 45.1 29.5 28.2
Single device-based 15.5 32.6 38.0
Multidevice-based 21.1 33.7 14.1
Other/unknown 18.3 4.2 19.7
NUTS2, Nomenclature of Territorial Units for Statistics level 2.
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Relevance for HTA Purpose
To assess whether RWD sources can be used to conduct HTA, we
asked whether they included information on health and economic
outcomes and comparators.
Health Outcomes
Almost all RWD sources included in our mapping included
health outcomes that are relevant for HTA. For arthroplasty,
four sources did not include data on health outcomes or informa-
tion was not retrievable (see spreadsheet). All sources on TAVI
and TMVR included at least one health outcome. For the da
Vinci robot, three German observational studies did not include
health outcomes or information was not available.
Some health outcomes were common to all case studies: mor-
tality, readmission (for hip/knee prostheses this often corresponds
with revision or reoperation), and patient-reported outcome mea-
sures (PROMs). PROMs were more commonly available for
arthroplasty, including pain assessment, using the Western
Ontario and McMaster Arthritis Center (WOMAC) score and
the Knee Society 18 Score. Instruments for measuring health-
related quality of life issues, such as EuroQol 5D (EQ5D),
the Health Utilities Index (HUI), and the Short Form 36 health
survey (SF-36), were also available for a minority of RWD sources.
For TAVI and TMVR, a consortium of experts, the “Valve
Academic Research Consortium” (VARC), established clinical
end points and standardized definitions (14). In 2011, the first
consensus document was published, and 2 years later, the selec-
tion and definitions of end points were revised and updated,
and named VARC-2 (15). In the selected sources, more than
half of RWD included end points defined according to either
VARC (twelve sources) or VARC-2 (forty-one sources).
The da Vinci case study included a broader variety of health
outcomes, given that we did not restrict the use of robotic surgery
to specific diagnoses. Health outcomes included intraoperative
outcomes (forty-one sources), among which the most reported
was blood loss (twenty-four sources), conversion to open/other
surgery (twenty-three sources), and postoperative complications
and relapse/recurrence (forty-four sources). We classified a resid-
ual group of health outcomes as “other.” They included very het-
erogeneous measures, such as recovery to normal breathing,
swallowing functions, and the oncological adequacy of resection.
Figure 1 shows the health outcomes for each case study and by
RWD type, selected based on how frequently they were available
and their similarity across case studies.
Resource Use
Compared with health outcomes, economic outcomes were less
frequently available, especially in the case of arthroplasty, for
which about one third of registries (eleven out of thirty-four)
and more than half of observational studies (fourteen out of
twenty-three) did not provide economic information.
For all case studies, the most commonly available information was
length of stay, which included various types such as hospital and ICU
length of stay, preintervention and postintervention length of stay and
so on. The other common economic outcome was the type of proce-
dure or procedure approach. In the case of arthroplasty, this referred
to whether the procedure was a revision or replacement, access, and
fixation methods. For TAVI and TMVR, it typically included whether
the access route was transfemoral, transaortic, trans-subclavian, or
transapical (16). The duration of surgery appeared particularly
important for the da Vinci robot and was reported in almost 70%
of sources (forty-nine). Hospitalization and procedure costs were
composite and mixed categories, and were often not described in
detail. The residual “other” group was composed of heterogeneous
information. This included, for example, outpatient visits, employ-
ment status, and the reduction of earning capacity. These were
costs relative to follow-up complications such as antithrombotic treat-
ment, the use of aortography, or echocardiography.
Figure 2 shows the economic outcomes for each case study and
by RWD type. These selections are based on how frequently they
were available and how similar they were across case studies.
Figure 1. Number of RWD sources that include health outcomes, by type of health outcome and case study. Note: HRQoL, health-related quality of life; PROMs,
patient-reported outcomes; VARC, Valve Academic Research Consortium.
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Comparators
For arthroplasty, eighteen sources (almost 25%) did not include
comparators suitable for HTA, and for six sources, the informa-
tion was unknown. The most commonly available comparators
were medical devices to be compared with other (types/versions
of) medical devices. This was most commonly the case for regis-
tries, where hip and knee prostheses were best traced. In other
cases, it was possible to compare the characteristics of different
devices (e.g., materials and characteristics of the components).
For TAVI and TMVR, thirty-one sources did not include com-
parators, mostly registries (twenty-one) and almost no interna-
tional sources allow to compare the medical device to other
devices or clinical procedures. In some of these cases, compari-
sons were made in terms of route of access (transfemoral vs. oth-
ers). When comparisons were possible, they were either between
TAVI-specific devices (e.g., Edwards Sapien vs. Medtronic
CoreValve)—this was typical in multidevice-based registries, or
between TAVI procedures and other procedures, commonly sur-
gery aortic valve replacement (SAVR).
For robotic surgery, twenty-six sources did not have compara-
tors for assessing the da Vinci robot, and for ten sources, it was
difficult to find such information. Almost half of the studies com-
pared robotic procedures with other types of surgeries, typically
laparoscopic or open surgeries or both. In some cases, compari-
sons were made between different versions of the da Vinci robot.
Figure 3 shows the comparators available in sources for each
case study and by RWD type, selected based on how frequently
they were available in each data source.
Discussion
RWD collection for medical devices in Europe is extensive and
growing, and the interest in using RWD to produce RWE has
increased in parallel. The key RWE uses for medical devices
include epidemiologic and safety evaluation, the characterization
of treatment patterns, and healthcare utilization trends (17).
The FDA has recently encouraged RWE use for regulatory
purposes (11). With the enactment of the new European
Medical Device Regulation, RWE will likely become an important
surveillance tool in Europe too. Given the considerable effort and
resources devoted to the collection of RWD, a greater return
would be achieved if the data were also useful for HTA. In this
work, we sought to assess, through a selection of medical devices,
whether existing sources are suitable for HTA and what, if any-
thing, should be done to maximize their potential.
We mapped existing RWD sources in Europe and critically
assessed whether they could be used for the HTA of medical
devices. We found that, depending on the characteristics of the
technology and the stage of the product lifecycle, certain types
of RWD sources are more commonly available. For the most
mature medical device—the endoprosthesis for arthroplasties—
registries are the most important source of RWD. The other
two technologies are, relative to the endoprosthesis, more recent,
and single- or multicenter observational studies are the main
sources of RWD here. This is especially true for the da Vinci
robot, which is a complex and expensive technology. For the
two technologies, most of the existing data sources are private,
and cross-technology comparisons are lacking.
Our mapping depicted a heterogeneous scenario across coun-
tries. Germany stands out for the number of RWD sources; this
has already been reported for cardiology (18). Some other coun-
tries seemed to lack RWD sources. This was particularly true for
some Eastern European countries. International or multicountry
studies proved a very important source, especially for TAVI and
TMVR and for the da Vinci robot.
In terms of the suitability of existing sources for HTA pur-
poses, several barriers emerged. Data accessibility is largely
restricted; there is a lack of standardization of health and eco-
nomic outcomes between countries and regions; economic out-
comes are included in most sources but are rather generic and
do not allow for the estimation of full costs; comparator(s)
often do not allow for comparisons between technologies, and
their data on health outcomes and resource use are not always
available. Finally, and critically, data quality and completeness,
Figure 2. Number of RWD sources that include economic outcomes, by type of resource and case study.
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and the availability of demographic and clinical variables to con-
trol for confounding vary from data source to data source. Data
integrity, meanwhile,—which refers to the accuracy and consis-
tency of data collected over the lifecycle of a medical technol-
ogy—proves difficult to assess.
The question of accessibility, or rather inaccessibility, has
important implications. Academic and nonacademic research is
strongly limited if existing data are not accessible, or if their exis-
tence is not disclosed. The finding that most RWD are not acces-
sible is a call for policy makers and regulators to take action to
facilitate data access, ensuring patients’ privacy and data protec-
tion, even when data come from private stakeholders.
Regarding standardization, there is a clear need for consistent
and appropriate selection, measurement, use, and reporting of
outcomes in clinical research and practice. The inconsistencies
and biases due to incomparable data on the effects of interven-
tions could be addressed with the development and application
of agreed standardized outcome sets, known as core outcome
sets (19). An attempt in this direction is represented by the clin-
ical end points for percutaneous transcatheter valve replacement,
for which a common set of outcomes have been established,
VARC, or VARC-2 end points. Another example is the joint col-
laboration and cross-country coordination promoted by the
European Federation of National Associations of Orthopaedics
and Traumatology that has created the Network of Orthopaedic
Registries of Europe. This network supports the development of
national and transnational arthroplasty registries and the develop-
ment of a minimum arthroplasty data set to enhance the compa-
rability of reports through standardization.
Overall, information on resource use is limited and includes
general indicators, such as length of stay and information on
the type of procedure. Only rarely specific costs related to the pro-
cedure type are included. Some variables, such as rehospitaliza-
tion and reoperation, here, were presented as health outcomes,
but they may also be considered as economic outcomes.
Importantly, for some registries, mostly in Scandinavian coun-
tries, data linkage is possible and, therefore, even if registries do
not directly include economic outcomes, these can be obtained
and/or expanded through other administrative data sets. It is
very important to enable as much as possible data linkage (20),
to avoid enlarging existing data sets with additional variables,
which is expensive in terms of costs and time, and to capitalize
on existing sources.
Comparators are often inadequate in comparative-effectiveness
research. In the case of TAVI, for example, there are important
ongoing discussions on its suitability for patients suffering from
severe aortic stenosis at low and intermediate risk (21). The num-
ber of studies and data that allow only specific and limited com-
parisons (e.g., old TAVI vs. improved TAVI, between procedure
approaches, etc) is increasing, but they have limited usefulness
and do not address the most important clinical questions around
this technology. Finally, the type and quality of information are a
necessary condition to guarantee the usability of RWD to produce
RWE. RWD/RWE could be an important source for HTA, but, as
of today, there is much to be done before they can provide the
main source of evidence for regulatory and/or reimbursement
decision making. Details on the variables collected are often avail-
able through the case report form. Much more rarely information
on missing values, outliers, and measurement errors are provided;
information on completeness, for example, is reported almost
only for registries. The provision of meta-data describing in
more detail the content of data sources might improve the assess-
ment of data integrity and quality. Existing scientific methods can
help to address bias descending from noninterventional data, but
their applicability is conditional on data quality.
Strengths and Limitations
A key strength of this RWD mapping is that findings are the result
of international collaboration and, therefore, we were able to use
local networks and knowledge to explore RWD sources available
in different countries and contexts in depth. Although this is a
unique strength, it also brings with it some limitations, because
the depth and scope of the mapping is subject to variability,
Figure 3. Number of RWD sources that include comparators, by type comparator and case study.
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depending on the researchers’ network. This may have played a
role particularly in those countries where our authors were not
based. We partly addressed this limitation with our systematic
search on PubMed and through expert advice.
The other strength of this work is that we did not focus on spe-
cific RWD types, as it has often been done, especially for registries
on hip and knee prostheses (e.g., Lübbeke et al. (22)). Moreover,
we considered different medical devices and we were able to char-
acterize the relevant types of RWD sources for each case not least
through comparison.
Finally, it should be noted that the nature and the purpose of
our mapping were not to identify and cover all existing sources.
Rather, we focused hard on the availability and usability of
RWD for HTA. To this end, we identified key sources (e.g.,
national registries and large observational studies) and we cap-
tured as many small-scale data sources as possible (e.g., multihos-
pital databases). Full coverage is beyond the scope of this work
and perhaps beyond the scope of any study, given that some
sources are not accessible and not identifiable through publica-
tions, personal knowledge, network, or other means.
Conclusions and Policy Recommendations
This mapping exercise and critical appraisal of RWD sources in
Europe, though focused on three specific case studies, allows for
general conclusions and policy recommendations beyond the
selected medical technologies.
First, the development of standardized approaches for the
design of RWD studies to make them more useful for HTA
would be warranted. Stronger coordination at the EU level to
leverage existing registries on devices currently scattered across
different Member States would be highly beneficial for allowing
the generation of comparable RWD across countries. These data
would also help in establishing a solid evidence base for a more
centralized HTA process, something presently under discussion
in EU. Along these lines, the development of standardized meta-
data describing data characteristics and their quality would repre-
sent a readily available tool for assessing whether the source is
potentially suitable to HTA. The information presented in the
extraction template of Supplementary Table 5, listing all RWD
sources, represents a first attempt in this direction, as a possible
list of elements to be described directly by data producers.
Sound policy recommendations on how to improve the usability
of RWD have already been proposed, for example for the use of
registries in support of regulatory decision making: see, for exam-
ple, the tools for assessing the usability of registries in support of
regulatory decision making produced by the International
Medical Device Regulators Forum (23).
Our study focuses on the content of the data sources and an
assessment of their suitability to HTA. We are not interested in
investigating the reasons for the setting up of specific registries/
observational studies or on the process that leads to their creation.
However, if (when) discussion at the EU level on the opportuni-
ties to anticipate the assessment of medical devices to earlier
stages of their lifecycle (i.e., early dialogue/early HTA) develops
further and the setting up of registries/observational studies
becomes a regulatory requirement, the type of data collected
will be of paramount importance to adequately inform policy
decisions.
Second, more efforts should be made to leverage on RWD to
produce comparative RWE. Comparative evidence can be derived,
for example, from a control group taken from historical cohorts in
administrative databases or well-designed patient registries.
Ideally, registries should be based on disease and should include
more than one device. They should also routinely collect informa-
tion on possible confounding factors and collect data on treat-
ment patterns and resource use over time.
Finally, to further strengthen the use of RWE, jurisdictions
need to develop a coordinated approach to the initiation, design,
and analysis of RWD, working together with manufacturers. Such
initiatives have been undertaken in various jurisdictions under
different labels (coverage with evidence development, perfor-
mance-based or risk-sharing agreements). They represent an
important opportunity to fill in evidence gaps.
Our study sheds light on a series of challenges that RWD
sources have if they are to be used for HTA purposes. If RWD
are to be considered an important source of evidence on the eco-
nomic and health impact of medical devices, there is a clear need
to improve quality, quantity, and access to these data sources. This
can only be achieved by coordinated and coherent actions across
different stakeholders and jurisdictions.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0266462321000301.
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